Showing results (971-980 of 1,996) with videos related to

Sort By:
Pageof 200
The Lancet. Neurology|December 20, 2024
Differential diagnosis and comparison of diagnostic algorithms in children and adolescents with autoimmune encephalitis in Spain: a prospective cohort study and retrospective analysisGemma Olivé-Cirera, Elianet Fonseca, Li-Wen Chen, et al.
The Lancet. Neurology|December 15, 2023
Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromesAntonio Farina, Macarena Villagrán-García, Alberto Vogrig, et al.
The Lancet. Neurology|January 24, 2024
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trialMikaël Mazighi, Martin Köhrmann, Robin Lemmens, et al.
The Lancet. Neurology|January 24, 2024
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for researchTanya Simuni, Lana M Chahine, Kathleen Poston, et al.
The Lancet. Neurology|March 20, 2024
Secondary stroke prevention in people with atrial fibrillation: treatments and trialsDavid J Seiffge, Virginia Cancelloni, Lorenz Räber, et al.
The Lancet. Neurology|March 20, 2024
Genetics of migraine: complexity, implications, and potential clinical applicationsHeidi G Sutherland, Bronwyn Jenkins, Lyn R Griffiths
The Lancet. Neurology|September 20, 2024
Brain volume change following anti-amyloid β immunotherapy for Alzheimer's disease: amyloid-removal-related pseudo-atrophyChristopher R S Belder, Delphine Boche, James A R Nicoll, et al.
The Lancet. Neurology|September 22, 2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trialsXavier Montalban, Patrick Vermersch, Douglas L Arnold, et al.
The Lancet. Neurology|February 16, 2024
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challengesJeremy Chataway, Thomas Williams, Vivien Li, et al.
The Lancet. Neurology|February 16, 2024
Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort studyAmaia Muñoz-Lopetegi, Mar Guasp, Laia Prades, et al.
Pageof 200